Sino Biological,Inc. (SHE:301047)
China · Delayed Price · Currency is CNY 76.86
-0.85 (-1.09%)
At close: Jan 22, 2026
Sino Biological,Inc. Revenue
Sino Biological,Inc. had revenue of 186.99M CNY in the quarter ending September 30, 2025, with 17.39% growth. This brings the company's revenue in the last twelve months to 660.17M, up 3.92% year-over-year. In the year 2024, Sino Biological,Inc. had annual revenue of 613.67M, down -5.06%.
Revenue (ttm)
660.17M
Revenue Growth
+3.92%
P/S Ratio
14.16
Revenue / Employee
646.59K
Employees
1,021
Market Cap
9.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 613.67M | -32.72M | -5.06% |
| Dec 31, 2023 | 646.39M | 71.79M | 12.49% |
| Jan 1, 2023 | 574.60M | -390.67M | -40.47% |
| Jan 1, 2022 | 965.27M | -631.02M | -39.53% |
| Dec 31, 2020 | 1.60B | 1.42B | 782.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.53B |
| Anhui Huaheng Biotechnology | 2.83B |
| Nanjing Vazyme Biotech | 1.34B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Chengdu Kanghua Biological Products | 1.21B |
| Shanghai Medicilon | 1.08B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| Bio-Thera Solutions | 845.32M |